More than 70% of individuals with difficult-to-treat depression who received ketamine achieved treatment response, and PET scans associated ketamine treatment with an increased amount of serotonin 1B receptors, according to a study in Translational Psychiatry. Dr. Johan Lundberg said ketamine is "very rapid-acting" but may also result in addiction, and using the serotonin 1B receptor as treatment target may lead to production of depression therapies without adverse effects.
PET sheds light on efficacy of ketamine in depression
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.